North Star Asset Management Inc. continued to hold its position in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,879 shares of the medical research company’s stock at the end of the second quarter. North Star Asset Management Inc.’s holdings in Amgen were worth $282,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Prudential Financial Inc. increased its position in shares of Amgen by 1.0% in the first quarter. Prudential Financial Inc. now owns 2,147,917 shares of the medical research company’s stock worth $322,037,000 after buying an additional 21,080 shares in the last quarter. Cottage Street Advisors LLC increased its position in shares of Amgen by 26.3% in the first quarter. Cottage Street Advisors LLC now owns 10,576 shares of the medical research company’s stock worth $1,596,000 after buying an additional 2,201 shares in the last quarter. Teachers Advisors Inc. increased its position in shares of Amgen by 2.1% in the first quarter. Teachers Advisors Inc. now owns 1,405,401 shares of the medical research company’s stock worth $210,712,000 after buying an additional 29,378 shares in the last quarter. Ngam Advisors L.P. increased its position in shares of Amgen by 9.6% in the first quarter. Ngam Advisors L.P. now owns 177,671 shares of the medical research company’s stock worth $26,639,000 after buying an additional 15,619 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its position in shares of Amgen by 0.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 445,830 shares of the medical research company’s stock worth $66,843,000 after buying an additional 2,960 shares in the last quarter. Institutional investors and hedge funds own 79.12% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.11% on Tuesday, hitting $162.80. The stock had a trading volume of 2,001,839 shares. The stock has a market cap of $121.83 billion, a PE ratio of 16.66 and a beta of 0.94. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85. The company’s 50 day moving average is $169.07 and its 200 day moving average is $162.61.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same quarter in the prior year, the firm earned $2.57 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Equities research analysts predict that Amgen Inc. will post $11.35 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 8th. Investors of record on Wednesday, November 16th will be given a $1.00 dividend. The ex-dividend date is Monday, November 14th. This represents a $4.00 dividend on an annualized basis and a yield of 2.46%. Amgen’s payout ratio is currently 40.90%.
A number of analysts have recently weighed in on the company. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $185.76 price objective for the company. in a research report on Tuesday, October 4th. Jefferies Group reissued a “buy” rating on shares of Amgen in a research report on Wednesday, September 28th. Citigroup Inc. lowered their price objective on Amgen from $175.00 to $172.00 and set a “neutral” rating for the company in a research report on Wednesday, September 28th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a research report on Wednesday, September 28th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and issued a $206.00 price objective (up previously from $204.00) on shares of Amgen in a research report on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $184.94.
In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.